Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
Stocks in this Quantisnow insightHealth Care
Historical context for PLSE
Across the 9 sessions after earlier PLSE headlines, the stock closed higher 5 times and lower 4 times, with a median move of 1.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PLSE | SPY |
|---|---|---|---|
| Dec 30, 2025 | Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference | -3.2% | -0.1% |
| Dec 22, 2025 | Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -0.4% | +0.6% |
| Dec 18, 2025 | Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation | +0.8% | +0.8% |
| Dec 9, 2025 | Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology | +1.5% | -0.1% |
| Nov 24, 2025 | Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +0.6% | +1.5% |
| Nov 7, 2025 | Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences | -1.7% | +0.1% |
Quantisnow market dataNASDAQ
PLSE
Pulse Biosciences Inc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2016
Get push alerts for PLSE
Full PLSE profile on Quantisnow Follow PLSE and get a push notification the moment its next story breaks.